Article Preview :
[ILLUSTRATION OMITTED] Two sites shuttered by the pharmaceutical giant Merck, one in Scotland and one in the Netherlands, will soon be humming again with the work of drug discovery. But the hum will not be business as usual. It will be the sound of a public-private consortium placing a high-stakes wager: a nearly 200-million [euro] (US$271-million) bet that it can boost a languishing pharmaceutical sector by fusing academic innovation with industrial-scale screening, using robots to test chemicals for biological activity. "If it really works, it might provide a future model to operate early drug discovery," says Jorg Huser, a champion of the idea who works at Bayer Healthcare in Wuppertal, Germany. The scheme, announced on 7 February, is sponsored by the Europe's Innovative Medicine Initiative. The European Commissions Seventh Framework Programme is contributing 80 million [euro] to the venture, with the remaining 116 million [euro] coming from in-kind contributions from industry partners and regional governments. Called the European Lead Factory, the consortium consists of 30 academic and corporate partners, and aims to fill company pipelines with promising drug candidates. The current dearth of candidates, Huser believes, is due to gaps...
Source Citation (MLA 8 th Edition)
Baker, Monya. "Europe bets on drug discovery: proponents hope consortium will revive flagging industry." Nature, vol. 494, no. 7435, 2013, p. 20. Academic OneFile, Accessed 25 Apr. 2019.
You Are Viewing A Preview Page of the Full ArticleThe article found is from the Gale Academic OneFile database.
You may need to log in through your institution or contact your library to obtain proper credentials.